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Abstract: Introduction: We aimed in this study to evaluate the benefit of Fluorine-18 (18F) fluorodeoxyglucose (FDG) 
positron emission tomography/computed tomography (PET/CT) in the detection of ovarian cancer recurrence in a 
selected patient group who had elevated serum Ca-125 levels and whether the recurrence appears by conventional 
imaging. 
Material and Method: A total of 39 female patients (mean age: 59±12.3) who underwent 18F-FDG PET/CT for restaging 
of ovarian cancer due to of elevated serum Ca-125 levels were retrospectively included to this study. 18F-FDG PET/CT 
imaging have been performed for searching possible disease recurrence in 24 patients who had normal or undetermined 
abdominal CT or pelvic MRI (Group 1) and evaluating to extent of disease in 15 patients who had abnormal abdominal 
CT or pelvic MRI (Group 2). Disease recurrence was confirmed by histopathological examination of surgical procedures 
or clinical follow-up data for at least 6 months period. 
Results: The mean period between the completion of initial treatment and 18F-FDG PET/CT was 2.6±1.4 years. In 33 of 
the 39 patients (82%), recurrent disease was developed during the follow-up period. Of the 33 patients with recurrent 
disease, 6 (18%) were confirmed by histopathological examination, while in 27 (82%) were documented by clinical 
follow-up. The mean Ca-125 level and the SUVmax value of group 1 were 509 U/ml (range 50.3-6544 U/ml) and 
12.26±4.9 (range 0-21.7), respectively. Overall sensitivity and specificity of 18F-FDG PET/CT in group 1 were quantified 
as 94% and 75%, respectively. The mean Ca-125 level and mean SUVmax value of group 2 at the time of 18F-FDG 
PET/CT scans were calculated as 358 U/ml (range 40.6-1233U/ml) and 11.4 ± 4.53 (range 4.5-20.1), respectively. 
Disease recurrence of 14 (93%) patients was correctly identified by 18F-FDG PET/CT. The sensitivity of 18F-FDG 
PET/CT in the detection of disease recurrence of group 2 was quantified as 100%. Specificity could not quantified due to 
absence of TN and FP results.  
Conclusions: 18F-FDG PET/CT has higher sensitivity and specificity in the detection recurrent ovarian cancer than 
serum Ca-125 levels and ceCT alone. The addition of 18F-FDG PET/CT to Ca-125 and ceCT improves the sensitivity of 
the evaluation of disease extension.  
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INTRODUCTION 
Ovarian cancer is the second most common 
gynecologic cancer. Patients were generally 
asymptomatic and tumor is spread beyond the ovary at 
the time of diagnosis [1]. Ovarian tumors are treated by 
a cytoreductive surgery following chemotherapy. 
Therefore disease recurrence is seen in most patients 
within 5 years period after initial treatment [2]. For this 
reason, a number of methods have been used for early 
diagnosis of recurrence. These methods include serial 
physical examinations, the measurement of serum Ca-
125 level and imaging modalities [3].  
Elevation of serum Ca-125 levels is a very sensitive 
marker for the prediction of ovarian cancer recurrence. 
However, a group of benign and malignant diseases  
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mayincrease serum Ca-125 levels [4, 5]. The 
anatomical localization of the recurrence is very 
important for planning of treatment strategies. Although 
computed tomography (CT) and magnetic resonance 
imaging (MRI) have been used for the detection of the 
localization of recurrent disease in patients who have 
increased serum Ca-125 levels, these methods have 
some limitations in the detection of small 
intraabdominal disseminated lesions and lymph node 
metastases as well as differentiation of the recurrence 
from postoperative or postradiation changes [6, 7, 8]. 
Integrated 18F-Fluorodeoxyglucose (18F-FDG) 
positron emission tomography (PET)/ computed 
tomography (CT) is a hybrid imaging modality which 
can provide anatomical and functional information 
together. It has been known that 18F-FDG PET/CT is 
superior than conventional imaging modalities in the 
restaging of several cancers by distinguishing 
recurrence from postoperative and postradiation 
changes and detecting small lymph node metastases. 
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Several studies have shown the role of 18F-FDG 
PET/CT in the detection of ovarian cancer recurrence 
[9, 10, 11]. We aimed in this study to evaluate the 
benefit of 18F-FDG PET/CT in the detection of ovarian 
cancer recurrence in a selected patient group who had 
elevated Ca-125 levels and whether or not the 
recurrence appears by conventional imaging. 
MATERIAL AND METHOD 
Patients 
A total of 39 female patients (mean age: 59±12.3) 
who underwent 18F-FDG PET/CT for restaging of 
ovarian cancer because of elevated Ca-125 levels 
were retrospectively included to this study. All the 
patients had undergone a cytoreductive surgery 
following chemotherapy for a previous diagnosis of 
ovarian epithelial tumors and they had been in a 
complete remission period before 18F-FDG PET/CT 
imaging. All the patients had elevated serum Ca-125 
levels (mean; 1080.2±551.7 U/ml, range; 40.6-
6544U/ml) during the procedure. Of the concurrent 
abdominal CT or pelvic MRI results, 18 patients had 
normal, 6 patients had undetermined and 15 patients 
had abnormal. As a results 18F-FDG PET/CT imaging 
have been performed for searching possible disease 
recurrence in 24 patients (group 1) and evaluating to 
progression of disease in 15 patients (group 2). 
Serum Ca-125 Measurements 
Serum Ca-125 levels of the patients had been 
measured by radioimmunometric assay method 
(normal range: 0-35 U/ml). 
18F-FDG PET/CT Imaging 
18F-FDG PET/CT images were acquired with a GE 
Discovery ST PET/CT scanner. During imaging 
patients were required at least 6 hour fasting and 
checked if their blood glucose levels were under 150 
mg/dl. Oral contrast agents were applied to all the 
patients. Whole body 18F-FDG PET/CT imaging was 
performed approximately 1 hour after an intravenous 
injection of 8-10 mCi 18F-FDG while the patients had 
been lied in supine position from the vertex to the 
proximal femur. During the waiting period the patients 
were rested in a quiet room without administrating 
muscle relaxant. PET images were acquired for 4 
minutes per bed position and emission PET images 
were reconstructed with non-contrast CT images which 
were obtained from the patients with the of a 
standardized protocol involving 140 kV, 70 mA, a tube 
rotation time of 0.5 s per rotation, a pitch of 6 and a 
 
Figure 1: Coronal CT, PET, fused PET/CT and maximum intensity projection images of whole body of 45 years old female 
patients. 18F-FDG imaging was performed for elevated Ca-125 levels (557 U/ml) and local recurrence detected by abdominal 
CT. 18F-FDG PET/CT revealed extra metastatic foci in abdominal and extraabdominal lymph nodes.  
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section thickness of 5 mm. Patients were allowed to 
breathe normally during procedure. Attenuation-
correction was done by PET/CT fusion images on three 
planes (transaxial, coronal and sagittal) and was 
reviewed by a Xeleris Workstation (GE Medical 
System). Any of patient has not been given diuretic to 
clear the bladder activity. 
Abdominal CT and Pelvic MRI Imaging 
Diagnostic contrast enhanced abdominal CT had 
been performed in 34 patients, while pelvic MRI 
imaging in 5 patients within three months period before 
PET/CT.  
Image Analysis 
Whole body 18F-FDG PET/CT images were 
interpreted visually and semi-quantitatively by two 
experienced nuclear medicine physician by consensus. 
The comparison was made between foci showing 
increased uptake and background/blood pool activity. 
Their anatomic confirmation was made with CT 
images. Foci with FDG uptake except physiological 
uptake sites, with their anatomic confirmation by CT 
images were assumed to be recurrent disease. 
Suspected CT findings without FDG uptake were 
accepted as negative for recurrence. Maximum 
standardized uptake value (SUVmax)s were quantified 
for all the pathological lesions.  
Follow-Up 
Disease recurrence was confirmed by 
histopathological examination results of surgical 
procedures or clinical follow-up data of at least 6 
months period. Clinical detected recurrence was 
accepted as progressive increase of serum Ca-125 
levels, concurrent CT/MRI findings or treatment 
response to chemotherapy.  
Statistical Analysis 
SPSS version 16.0 was used for statistical analysis. 
Student T test was used for comparison of mean 
values of different groups. A receiver operating curve 
(ROC) analysis was performed for description of cut-off 
values. Sensitivity and specificity were quantified by 
using TP, FP, TN and FN values for each imaging 
modalities.  
RESULTS 
This study included a total of 39 female patients 
(mean age: 59±12.3, range:) who underwent 18F-FDG 
PET/CT for restaging of ovarian cancer caused of 
elevated Ca-125 levels. The mean period between the 
completion of initial treatment and 18F-FDG PET/CT 
was 2.6±1.4 years. The primary tumor localization was 
left, right and bilateral over in 9 (23%), 17 (43%) and 13 
(33%) patients respectively. Detailed pathological 
results of 26 patients could be reached. All the patients 
had a previous diagnosis of malignant ovarian epithelial 
tumors (22 serous cyst-adenocarcinoma, 3 
endometrioid type tumor, 1 undifferentiated tumor) and 
elevated Ca-125 levels (mean; 1080.2U/ml, range; 
40.6-6544U/ml). 
Overall, 33 (82%) out of the 39 patients developed 
recurrent disease during the follow-up period (Table 1). 
Of the 33 patients with recurrent disease, 6 (18%) were 
confirmed by histopathological examination, while in 27 
   
Figure 2: Transaxial CT, PET images. Fifty-one years old patient. 18F-FDG PET imaging was performed for elevated Ca-125 
levels (60 U/ml) but recurrence not detected by ceCT. 18F-FDG PET/CT revealed foci in liver. 
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(82%) were documented by clinical follow-up. 18F-FDG 
PET/CT was positive in 32 (96%) patients with 
recurrent disease. Of one patient (4%) who has a 
recurrence in pleural fluid, disease recurrence could 
not be detected by 18F-FDG PET/CT.  
In the detailed evaluation of 18F-FDG PET/CT 
indications, 18F-FDG PET/CT scan was performed for 
searching of possible disease recurrence in 24 (61%) 
patients who had normal or undetermined abdominal 
CT/pelvic MRI scans and elevated Ca-125 levels 
(group 1). The mean Ca-125 level and the SUVmax 
value of group 1 were 509 U/ml (range 50.3-6544 U/ml) 
and 12.26±4.9 (range 0-21.7), retrospectively. Of these 
24 18F-FDG PET/CT scans, 18 (75%) correctly 
showed the disease recurrence. However, 18F-FDG 
PET/CT scan was FP and FN in 1 (4%) and 1 (4%) 
patient respectively, while it was TN in 3 (12%) 
patients. Disease recurrence was confirmed by 
histopathological examination in 3 (12%) patients and 
clinical follow up in 16 (66%) patients during the follow-
up period. In the remaining one patient in this group, 
secondary breast cancer was detected by surgical 
removal of FDG positive breast lesion. This patient was 
excluded from statistical analysis. Overall sensitivity 
and specificity of 18F-FDG PET/CT in this group was 
quantified as 94% and 75%, respectively.  
18F-FDG PET/CT scan was performed for 
evaluating the progression of disease in 15 patients 
who had elevated Ca-125 levels and abnormal findings 
in abdominal CT or pelvic MRI (group 2). The mean 
Ca-125 level and mean SUVmax value of this group at 
the time of 18F-FDG PET/CT scans were quantified as 
358 U/ml (range 40.6-1233U/ml) and 11.4 ± 4.53 
(range 4.5-20.1), respectively. Disease recurrence of 
14 (93%) patients was correctly identified by 18F-FDG 
PET/CT. Of the 3(20%) patients, the recurrence was 
documented by histopathological examinations, while it 
was confirmed by clinically in the rest (73%) of them. 
Additionally, 18F-FDG PET/CT was detected extra 
lesions which were not identified by CT or MRI in 8 
(53%) patients (lymph nodes in 5 patients, liver in 3 
patients and peritoneal implants in 3 patients). The rest 
one patient who had FDG positive peritoneal implants 
and lymph nodes was diagnosed as having secondary 
sigmoid colon cancer after 18F-FDG PET/CT scan. 
This patient was excluded from statistical analysis. The 
sensitivity of 18F-FDG PET/CT in the detection of 
disease recurrence was calculated as 100%. Specificity 
could not be calculated because of the absence of TN 
and FP results.  
Overall sensitivity and specificity of 18F-FDG 
PET/CT in the detection of ovarian cancer recurrence 
in patients who have elevated Ca-125 levels was 
computed as 96% and 75%, respectively. The mean 
Ca-125 level of whole patient group was 1080.2U/ml 
(range 40.6-6544U/ml) at the time of the procedure. 
The mean Ca-125 level was 540.07 U/ml (range 40.6-
6544 U/ml) in patients with TP scans, while 175.19 
Table 1: 18F-FDG PET/CT Results in the Detection of Recurrent Disease According to Indications of the PET/CT Scan 
Indication of 18F-FDG PET/CT No of patients  






Elevated Ca-125 levels and negative or indeterminate conventional imaging 24 (61%) 20 (83%) 19 (79%) 
Elevated Ca-125 levels and positive conventional imaging  15 (39%)  15 (100%)  14 (93%) 
Table 2: Comparison of the Results of 18F-FDG PET/CT and Conventional Imaging Modalities 
Negative or indeterminate 
convantional imaging 
Positive conventional imaging Overall  
 CT/MRI 18F-FDG PET/CT CT/MRI 18F-FDG PET/CT CT/MRI 18F-FDG PET/CT 
True positive (n) 6 18 14 14 20 32 
True negative (n) 4 3 0 0 4 3 
False positive (n) 0 1 0 0 0 1 
False negative (n) 13 1 0 0 12 1 
Sensitivity (%) 31 94 100 100 62 96 
Specificity (%) 100 75 N/A N/A N/A 75 
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U/ml (range 50.3-300) in patients with TN scans. The 
difference between mean Ca-125 levels of patients with 
TP and TN was not statistically significant (P>0.05).  
Although abdominal CT or pelvic MRI correctly 
revealed the disease recurrence of 20 patients, they 
were false negative in 12 patients. The sensitivity of 
conventional imaging modalities was found to be 62% 
in the detection of recurrent disease. The specificity 
could not be calculated because of the absence of FP 
and TN scan.  
In the ROC analysis, we found a 5.4 cut-off 
SUVmax value for the prediction of recurrent disease 
with a 93% sensitivity and 75% specificity. 
DISCUSSION 
Despite performing latest technology in the 
diagnosis and treatment of ovarian cancer, today it still 
remains the leading gynecological cause of dead. The 
main reason of the low rates of 5 years survival is the 
recurrence of disease [12]. For this reason imaging 
modalities has been focused on early detection of the 
recurrence. CT or MRI has been routinely used to 
investigate of recurrence and it has been known that 
abdominal diagnostic CT has 85-93% sensitivity in 
these cases. In spite of this, elevation of serum Ca-125 
level is seen about 3-6 months before the clinical 
detection of recurrence [4, 5]. The early detection of 
recurrence in this period may improve the prognosis of 
patients with recurrent ovarian cancer. 
18F-FDG PET/CT is a useful imaging modality in 
the detection of recurrence of several cancers. It has 
been known 18F-FDG PET/CT is superior than 
conventional imaging modalities in the restaging of 
several cancers by distinguishing recurrence from 
postoperative and postradiation changes and detecting 
small lymph node metastases. In several studies, the 
sensitivity and specificity of 18F-FDG PET/CT in the 
detection of ovarian cancer recurrence have been 
reported as 83-95% and 71-100%, respectively [13-16]. 
Similarly, we found an overall 96% sensitivity and 75% 
specificity in our whole patient group.  
The superiority of 18F-FDG PET/CT over 
conventional imaging modalities has been reported. 
The reported sensitivity of CT in the detection of 
ovarian cancer recurrence is 55-73% [17, 19]. We 
found a 62% sensitivity rate for conventional imaging 
modalities. 18F-FDG PET/CT especially seem to be 
superior in patients who have elevated serum Ca-125 
levels and negative or indeterminate conventional 
imaging results. While 18F-FDG PET/CT revealed the 
disease recurrence in 18 out of 19 patients who had 
confirmed recurrence, conventional imaging modalities 
were negative in 12 of them. Of these 12 patients, 8 
patients had FDG positive peritoneal implants, 3 
patients had FDG positive lymph nodes and 2 patients 
had FDG positive liver metastases. It is known that 
conventional imaging modalities have lower sensitivity 
in the detection of millimetric peritoneal implants or 
millimetric lymph nodes [20]. However despite 1 cm 
spatial resolution limit of PET imaging, 18F-FDG 
PET/CT can detect millimetric peritoneal or lymph node 
metastases in patients who had tumors with high 
metabolic activity. Thrall et al. [13] have reported 18F-
FDG PET/CT results of 39 patients who had ovarian 
cancer. They have shown usefulness of 18F-FDG 
PET/CT in the detection of ovarian cancer recurrence, 
especially in patients with elevated Ca-125 levels and 
negative conventional imaging.  
We also evaluated the performance of 18F-FDG 
PET/CT in the detection of extent of the disease in 
patients who had elevated Ca-125 levels and abnormal 
conventional imaging. Accurate staging of disease is 
very important in this patient group for the application 
of subsequent treatment options. Mangili et al. [10] 
have compared the success of 18F-FDG PET/CT and 
CT in the detection of ovarian cancer recurrence. They 
have reported a 44% changing rate of clinical 
management of patients when 18F-FDG PET/CT 
results were added to CT results. Similarly, Simcock et 
al. [21] have described a change in the management of 
58% of the patients with 18F-FDG PET/CT information. 
In our patients, 18F-FDG PET/CT was detected 
additional foci in the 8 (53%) patients (lymph nodes 
(n:5), liver (n:3) and peritoneal implants (n:3)).  
A total of 2 secondary primary cancers were 
detected in the follow-up period of our study. The first 
of them was in one patient who had a single FDG 
uptake in the left breast. Because the unexpected 
localization of this lesion for ovarian cancer recurrence 
and the possibility of simultaneously presence of breast 
cancer, the patient underwent an excisional biopsy 
from this lesion and diagnosed as breast cancer. Of the 
second patient, 18F-FDG PET/CT showed FDG 
positive peritoneal implants and lymph nodes. After 
18F-FDG PET/CT imaging, the patient underwent a 
surgical procedure because of the development of ileus 
symptoms and diagnosed as sigmoid colon cancer 
histopathologically. If ileus had not developed this 
patient probably could be treated as recurrence of 
ovarian cancer. Because the distinction or suspicion of 
the presence of secondary cancer would not be 
possible with these 18F-FDG PET/CT findings.  
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Results of our study support the high sensitivity and 
specificity of 18F-FDG PET/CT in the detection of 
ovarian cancer recurrence and evaluation of disease 
progression. However, there were some limitations of 
this study. Firstly, since the retrospective design of the 
study, conventional imaging modalities of patients 
could not be standardized. Secondly, confirmation of 
disease recurrence could be done just in 6 patients. 
New, randomized, prospective studies are needed to 
support our results. 
CONCLUSION  
18F-FDG PET/CT has higher sensitivity and 
specificity in the detection recurrent ovarian cancer 
than serum Ca-125 levels and ceCT alone. 
Nevertheless 18F-FDG PET/CT has high value in 
cases with increased Ca-125 level but there is no exact 
evidence by ceCT. The addition of 18F-FDG PET/CT to 
Ca-125 and ceCT improves the sensitivity of the 
evaluation of disease extension. 
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